Achilla, E, McCrone, P (2013) The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Applied Health Economics and Health Policy, 11: 95–106.
Adams, CE, Fenton, MKP, Quraishi, S et al (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry, 179: 290–9.
Addington, D, Bouchard, R-H, Goldberg, J et al (2005) Clinical Practice Guidelines: Treatment of Schizophrenia. Canadian Journal of Psychiatry, 50 (suppl 1): s1–56.
Álamo, C, López-Muñoz, F (2013) The pharmacological role and clinical applications of antipsychotics' active metabolites: paliperidone versus risperidone. Clinical and Experimental Pharmacology, 3 (1): 117.
Argo, TR, Crismon, ML, Miller, AL et al (2007) Texas Medication Algorithm Project Procedural Manual: Schizophrenia Treatment. Texas Department of State Health Services.
Barnes, TRE, Shingelton-Smith, A, Paton, C (2009) Antipsychotic long-acting injections: prescribing practice in the UK. British Journal of Psychiatry, 195 (suppl 52): s37–42.
Chopra, P, Hamilton, B, Castle, D et al (2009) Implementation of the Strengths Model at an area mental health service. Australasian Psychiatry, 17: 202–6.
da Silva Freire Coutinho, E, Fenton, M, Quraishi, SN (2009) Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database of Systematic Reviews, 3: CD001164.
Day, JC, Wood, G, Dewey, M et al (1995) A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. British Journal of Psychiatry, 166: 650–3.
de Hert, M, Schreurs, V, Vancampfort, D et al (2009) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry, 8: 15–22.
Dibonaventura, M, Gabriel, S, Dupclay, L et al (2012) A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry
Emsley, R, Oosthuizen, P, Koen, L et al (2008) Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International Clinical Psychopharmacology, 23: 325–31.
Gopalakrishna, G, Aggarwal, A, Lauriello, J (2013) Long-acting aripiprazole: how might if fit into our tool box?
Clinical Schizophrenia & Related Psychoses, 7: 87–92.
Gray, R, Spilling, R, Burgess, D et al (2009) Antipsychotic long-acting injections in clinical practice: medication management and patient choice. British Journal of Psychiatry, 195 (suppl 52): s51–6.
Green, AI, Drake, RE, Brunette, MF et al (2007) Schizophrenia and co-occurring substance use. American Journal of Psychiatry, 164: 402–8.
Green, A (2012) Long-acting injectable antipsychotic medications in patients with comorbid schizophrenia and substance use disorders. Journal of Dual Diagnosis, 8: 62–3.
Haddad, P, Lambert, T, Lauriello, J (2011) The role of antipsychotic long-acting injections in current practice. In Antipsychotic Long-Acting Injections (eds Haddad, P, Lambert, T, Lauriello, J) 241–60. Oxford University Press.
Haro, JM, Suarez, D, Novick, D et al (2007) Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. European Neuropsychopharmacology, 17: 235–44.
Harrow, M, Jobe, TH (2007) Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. Journal of Nervous and Mental Disease, 195: 406–14.
Heres, S, Schmitz, FS, Leucht, S et al (2007) The attitude of patients towards antipsychotic depot treatment. International Clinical Psychopharmacology, 22: 275–82.
Jaeger, M, Rossler, M (2010) Attitudes towards long-acting antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Research, 175: 58–62.
Johnson, DAW (2009) Historical perspective on antipsychotic long-acting injections. British Journal of Psychiatry, 195 (suppl 52): s7–12.
Kane, JM, Garcia-Ribera, C (2009) Clinical guideline recommendations for antipsychotic long-acting injections. British Journal of Psychiatry, 195 (suppl 52): s63–7.
Kirson, NY, Weiden, PJ, Yermakov, S et al (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesising results across different research designs. Journal of Clinical Psychiatry, 74: 568–75.
Koola, MM, Wehring, HJ, Kelly, DL (2012) The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. Journal of Dual Diagnosis, 8: 50–61.
Kreyenbuhl, J, Buchanan, RW, Dickerson, FB et al (2010) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophrenia Bulletin, 36: 94–103.
Kuehn, BM (2013) FDA investigates deaths related to use of olanzapine. JAMA, 310: 361.
Lehman, AF, Lieberman, JA, Dixon, LB et al (2010) Practice Guideline for the Treatment of Patients with Schizophrenia (2nd edn). American Psychiatric Association.
Leucht, C, Heres, S, Kane, JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised controlled long term trials. Schizophrenia Research, 127: 83–92.
McCabe, R, Bullenkamp, J, Hansson, L et al (2012) The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. PLoS One, 7 (4): e36080.
McEvoy, JP, Byerly, M, Hamer, RM et al (2014) Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA, 311: 1978–87.
National Institute for Health and Care Excellence (2014) Psychosis and Schizophrenia in Adults: Treatment and Management (NICE Clinical Guideline 178). NICE.
O'Donoghue, B, Lyne, J, Renwick, L et al (2012) A descriptive study of ‘non-cases’ and referral rates to an early intervention for psychosis service. Schizophrenia Research, 6: 276–82.
Offord, S, Wong, B, Mirski, D et al (2013) Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. Journal of Medical Economics, 16: 231–9.
Olfson, M, Marcus, SC, Ascher-Svanum, H (2007) Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophrenia Bulletin, 33: 1379–87.
Patel, MX, David, AS (2005) Why aren't depot antipsychotics prescribed more often and what can be done about it?
Advances in Psychiatric Treatment, 11: 203–11.
Patel, MX, Taylor, M, David, AS (2009) Antipsychotic long-acting injections: mind the gap. British Journal of Psychiatry, 195 (suppl 52): s1–4.
Patel, MX, Haddad, PM, Chaudhry, IB et al (2010) Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long acting injections: comparisons over 5 years. Journal of Psychopharmacology, 24: 1473–82.
Rosenheck, RA, Krystal, JH, Lew, R et al (2011) Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine, 364: 842–51.
Rubio, G, Martinez, I, Ponce, G et al (2006) Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian Journal of Psychiatry, 51: 531–8.
Stanhope, V, Marcus, S, Solomon, P (2009) The impact of coercion on services from the perspective of mental health care consumers with co-occurring disorders. Psychiatric Services, 60: 183–8.
Staring, ABP, Van der Gaag, M, Koopmans, GT et al (2010) Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. British Journal of Psychiatry, 197: 448–55.
Taylor, D (2009) Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. British Journal of Psychiatry, 195 (suppl 52): s13–9.
Tiihonen, J, Wahlbeck, K, Lonnqvist, J et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of 2230 patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ, 333: 224.
Tiihonen, J, Haukka, J, Taylor, M et al (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry, 168: 603–9.
Vázquez Vázquez, JM, González-Rodríquez, A, Sanz Asin, P et al (2012) EPA-0354 – Efficacy and tolerability of long-acting injectable paliperidone palmitate in the treatment of dual psychosis [Abstract]. European Psychiatry, 29 (suppl 1): 1.
Velligan, DI, Wang, M, Diamond, P et al (2007) Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Services, 58: 1187–92.
Waddell, L, Taylor, M (2009) Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. British Journal of Psychiatry, 195 (suppl 52): s43–50.
Walburn, J, Gray, R, Gournay, K et al (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry, 179: 300–7.
West, JC, Marcus, SC, Wilk, J et al (2008) Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophrenia Bulletin, 34: 995–1001.
Zhornitsky, S, Stip, E (2012) Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophrenia Research and Treatment, 2012: ID 407171.
Zhu, B, Ascher-Svanum, H, Shi, L et al (2008) Time to discontinuation of depot and oral first generation antipsychotics in the usual care of schizophrenia. Psychiatric Services, 59: 315–7.